Premium Content Editorial content

Immuno-oncology dominates big pharma’s deal agenda

With the first wave of cancer immunotherapies continuing to show their potential to revolutionize treatment paradigms, major pharmaceutical companies are leaving no stone unturned in the search for winning combination therapies that harness immuno-oncology drugs.

Please sign in or register for FREE

Register to BioPharma Dealmakers

From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.


No comments yet.